JP2013512903A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013512903A5 JP2013512903A5 JP2012542060A JP2012542060A JP2013512903A5 JP 2013512903 A5 JP2013512903 A5 JP 2013512903A5 JP 2012542060 A JP2012542060 A JP 2012542060A JP 2012542060 A JP2012542060 A JP 2012542060A JP 2013512903 A5 JP2013512903 A5 JP 2013512903A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- compound according
- heterocyclyl
- alkyl
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 112
- 125000000623 heterocyclic group Chemical group 0.000 claims description 62
- 229910052717 sulfur Inorganic materials 0.000 claims description 34
- 125000001072 heteroaryl group Chemical group 0.000 claims description 33
- 229910052760 oxygen Inorganic materials 0.000 claims description 30
- 125000005842 heteroatom Chemical group 0.000 claims description 27
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 26
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 24
- 125000003107 substituted aryl group Chemical group 0.000 claims description 24
- 229910052757 nitrogen Inorganic materials 0.000 claims description 22
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 20
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 18
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 12
- 210000004027 cell Anatomy 0.000 claims description 12
- 239000012453 solvate Substances 0.000 claims description 12
- 125000005884 carbocyclylalkyl group Chemical group 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 10
- 125000005843 halogen group Chemical group 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 229940002612 prodrug Drugs 0.000 claims description 10
- 239000000651 prodrug Substances 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 7
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 7
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 6
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000003282 alkyl amino group Chemical group 0.000 claims description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 4
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims description 4
- 102000052052 Casein Kinase II Human genes 0.000 claims description 4
- 108010010919 Casein Kinase II Proteins 0.000 claims description 4
- 108091000080 Phosphotransferase Proteins 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 201000005787 hematologic cancer Diseases 0.000 claims description 4
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 125000003884 phenylalkyl group Chemical group 0.000 claims description 4
- 102000020233 phosphotransferase Human genes 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 4
- 230000033115 angiogenesis Effects 0.000 claims description 3
- 230000004663 cell proliferation Effects 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 2
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 2
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 210000003128 head Anatomy 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000010235 heart cancer Diseases 0.000 claims description 2
- 208000024348 heart neoplasm Diseases 0.000 claims description 2
- 208000026278 immune system disease Diseases 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 210000001165 lymph node Anatomy 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 208000026037 malignant tumor of neck Diseases 0.000 claims description 2
- 125000002950 monocyclic group Chemical group 0.000 claims description 2
- 210000003739 neck Anatomy 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 230000001717 pathogenic effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 208000019553 vascular disease Diseases 0.000 claims description 2
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 0 CCCCN=C(*C)C(CCCC*C(*)=C(C)C(C)=C)=C(C)I*C(C)CC*C=C(C)N(*)[*+]C Chemical compound CCCCN=C(*C)C(CCCC*C(*)=C(C)C(C)=C)=C(C)I*C(C)CC*C=C(C)N(*)[*+]C 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 230000009707 neogenesis Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26680109P | 2009-12-04 | 2009-12-04 | |
| US61/266,801 | 2009-12-04 | ||
| US35416510P | 2010-06-11 | 2010-06-11 | |
| US61/354,165 | 2010-06-11 | ||
| PCT/US2010/056712 WO2011068667A1 (en) | 2009-12-04 | 2010-11-15 | Pyrazolopyrimidines and related heterocycles as ck2 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013512903A JP2013512903A (ja) | 2013-04-18 |
| JP2013512903A5 true JP2013512903A5 (enExample) | 2013-12-19 |
| JP5802676B2 JP5802676B2 (ja) | 2015-10-28 |
Family
ID=44115232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012542060A Active JP5802676B2 (ja) | 2009-12-04 | 2010-11-15 | Ｃｋ２阻害剤としてのピラゾロピリミジンおよび関連複素環化合物 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8575177B2 (enExample) |
| EP (1) | EP2509602B9 (enExample) |
| JP (1) | JP5802676B2 (enExample) |
| KR (1) | KR101851130B1 (enExample) |
| CN (1) | CN102762208A (enExample) |
| AU (1) | AU2010326268B2 (enExample) |
| BR (1) | BR112012013508A2 (enExample) |
| CA (1) | CA2782684C (enExample) |
| ES (1) | ES2629170T3 (enExample) |
| IL (1) | IL220086B (enExample) |
| PL (1) | PL2509602T3 (enExample) |
| RU (1) | RU2607453C2 (enExample) |
| SG (1) | SG181507A1 (enExample) |
| WO (1) | WO2011068667A1 (enExample) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9199999B2 (en) * | 2010-06-01 | 2015-12-01 | Bayer Intellectual Property Gmbh | Substituted imidazopyrazines |
| NZ753024A (en) | 2010-06-03 | 2020-08-28 | Pharmacyclics Llc | The use of inhibitors of bruton’s tyrosine kinase (btk) |
| WO2012170827A2 (en) * | 2011-06-08 | 2012-12-13 | Cylene Pharmaceuticals, Inc. | Pyrazolopyrimidines and related heterocycles as ck2 inhibitors |
| EP2723746A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| JP5408389B1 (ja) * | 2012-04-27 | 2014-02-05 | 新日鐵住金株式会社 | 継目無鋼管及びその製造方法 |
| KR102427777B1 (ko) | 2012-06-26 | 2022-08-01 | 델 마 파마슈티컬스 | 디안하이드로갈락티톨, 디아세틸디안하이드로갈락티톨, 디브로모둘시톨, 또는 그의 유사체 또는 유도체를 이용하여 유전학적 다형성이 있는 환자에 있어서 티로신-키나아제-억제제 내성 악성종양, ahi1 조절곤란 또는 돌연변이를 치료하는 방법 |
| TW201414737A (zh) * | 2012-07-13 | 2014-04-16 | 必治妥美雅史谷比公司 | 作爲激酶抑制劑之咪唑并三□甲腈 |
| CA2879570A1 (en) | 2012-07-24 | 2014-01-30 | Pharmacyclics, Inc. | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
| US9340546B2 (en) | 2012-12-07 | 2016-05-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| ES2649156T3 (es) | 2013-01-14 | 2018-01-10 | Incyte Holdings Corporation | Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim |
| US9200004B2 (en) | 2013-01-15 | 2015-12-01 | Incyte Holdings Corporation | Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors |
| JP2016512239A (ja) | 2013-03-15 | 2016-04-25 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼの阻害剤として有用な化合物 |
| WO2014143242A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| US9663519B2 (en) | 2013-03-15 | 2017-05-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| JP2016519684A (ja) | 2013-04-08 | 2016-07-07 | デニス エム ブラウン | 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物 |
| CN103360399B (zh) * | 2013-08-02 | 2016-03-02 | 北京大学 | 6-芳基取代-咪唑-[1,2-b]哒嗪类衍生物，其制备方法及用途 |
| PE20160532A1 (es) | 2013-08-23 | 2016-05-21 | Incyte Corp | Compuesto de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim |
| CN103570728B (zh) * | 2013-11-12 | 2015-12-30 | 山东大学 | 一种取代吡唑并[1,5-a]嘧啶类衍生物及其制备方法与应用 |
| WO2015085132A1 (en) | 2013-12-06 | 2015-06-11 | Vertex Pharmaceuticals Incorporated | 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof |
| ES2702126T3 (es) * | 2013-12-10 | 2019-02-27 | Bristol Myers Squibb Co | Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa |
| TWI534148B (zh) * | 2014-02-13 | 2016-05-21 | 生華生物科技股份有限公司 | 吡唑並嘧啶前藥及其使用方法 |
| GB201403093D0 (en) | 2014-02-21 | 2014-04-09 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| TWI709561B (zh) * | 2014-05-28 | 2020-11-11 | 瑞士商諾華公司 | 新穎吡唑并嘧啶衍生物 |
| CN107074863B (zh) | 2014-06-05 | 2019-12-03 | 沃泰克斯药物股份有限公司 | Atr激酶抑制剂的制备方法及其不同的固体形式 |
| CA2950780C (en) | 2014-06-17 | 2023-05-16 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of chk1 and atr inhibitors |
| US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| CN105457029A (zh) * | 2014-09-29 | 2016-04-06 | 中国科学院上海巴斯德研究所 | 抑制酪蛋白激酶2活性在促进i型干扰素表达的应用 |
| AU2015360416A1 (en) * | 2014-12-10 | 2017-06-08 | Massachusetts Institute Of Technology | Fused 1,3-azole derivatives useful for the treatment of proliferative diseases |
| BR112017015828B1 (pt) * | 2015-01-23 | 2020-02-18 | Glaxosmithkline Intellectual Property Development Limited | Compostos derivados de pirazolo[3,4-d]pirimidina, composição farmacêutica e combinação compreendendo ditos compostos e uso dos mesmos para o tratamento de leishmaniose |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
| HK1258570A1 (zh) | 2015-09-30 | 2019-11-15 | Vertex Pharmaceuticals Inc. | 使用dna损伤剂及atr抑制剂的组合治疗癌症的方法 |
| WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| CN109071456A (zh) | 2016-02-16 | 2018-12-21 | 麻省理工学院 | 作为myc调节剂的max结合剂及其用途 |
| WO2017223432A1 (en) * | 2016-06-24 | 2017-12-28 | Polaris Pharmaceuticals | Ck2 inhibitors, compositions and methods thereof |
| AU2018256459B2 (en) | 2017-04-21 | 2023-12-07 | Ikena Oncology, Inc. | Indole AHR inhibitors and uses thereof |
| CN107188901A (zh) * | 2017-05-27 | 2017-09-22 | 无锡捷化医药科技有限公司 | 一种(3‑(3‑(二甲氨基)丙氧基)苯基)硼酸的制备方法 |
| FI3658552T3 (fi) | 2017-07-28 | 2023-11-16 | Yuhan Corp | Menetelmä n-(5-((4-(4-((dimetyyliamino)metyyli)-3-fenyyli-1h-pyratsol-1-yyli)pyrimidin-2-yyli)amino)-4-metoksi-2-morfolinofenyyli)akryyliamidin valmistamiseksi saattamalla vastaava amiini reagoimaan 3-halopropionyylikloridin kanssa |
| CN111194317A (zh) | 2017-07-28 | 2020-05-22 | 林伯士拉克许米公司 | Tyk2抑制剂与其用途 |
| GB201715194D0 (en) | 2017-09-20 | 2017-11-01 | Carrick Therapeutics Ltd | Compounds and their therapeutic use |
| TW201924683A (zh) | 2017-12-08 | 2019-07-01 | 美商英塞特公司 | 用於治療骨髓增生性贅瘤的低劑量組合療法 |
| US11071727B2 (en) | 2018-01-26 | 2021-07-27 | Northwestern University | Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene product (MLL1) by taspase1 using kinase inhibitors |
| BR112021008176A2 (pt) | 2018-10-30 | 2021-08-03 | Kronos Bio, Inc. | compostos, composições, e métodos para a modulação da atividade da cdk9. |
| CN112608316B (zh) * | 2019-07-30 | 2022-10-21 | 厦门宝太生物科技股份有限公司 | 一种吡唑并三嗪类腺苷受体拮抗剂 |
| CA3159317A1 (en) | 2019-11-26 | 2021-06-03 | Alfredo C. Castro | Polymorphic carbazole derivatives and uses thereof |
| GB201918541D0 (en) | 2019-12-16 | 2020-01-29 | Carrick Therapeutics Ltd | Therapeutic compounds and their use |
| KR102337404B1 (ko) * | 2020-01-03 | 2021-12-10 | 연세대학교 산학협력단 | 조직 재생용 조성물 |
| IL296927B2 (en) * | 2020-03-30 | 2025-11-01 | Senhwa Biosciences Inc | Antiviral compounds and method for treating rna viral infection, particularly covid-19 |
| IL301052A (en) * | 2020-09-15 | 2023-05-01 | Mitsubishi Tanabe Pharma Corp | A triazine compound salt, its crystal form, and its production method |
| KR20230129291A (ko) * | 2021-01-09 | 2023-09-08 | 버그웍스 리서치 인코포레이션 | 아데노신 2A 수용체 및 아데노신 2B 수용체 길항제로서의 디아미노피라졸로[1,5-a]피리미딘-6-카르보니트릴 화합물 |
| US12343421B2 (en) * | 2021-11-01 | 2025-07-01 | Solaana MD LLC | Vitamin D base layer |
| AU2024233204A1 (en) * | 2023-03-09 | 2025-09-25 | Aquinnah Pharmaceuticals, Inc. | Inhibitors of tdp-43 and tau aggregation |
| US12269826B1 (en) * | 2023-11-16 | 2025-04-08 | King Faisal University | 7H-pyrido[4′,3′:4,5]pyrrolo[2,3-c][1,7]naphthyridine compounds as CK2 inhibitors |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5624677A (en) | 1995-06-13 | 1997-04-29 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
| TWI238064B (en) * | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| JP2005513026A (ja) * | 2001-11-15 | 2005-05-12 | インサイト サン ディエゴ インコーポレイテッド | 高コレステロール血症、異脂肪血症および他の代謝障害；癌、および他の疾患を治療するｎ−置換複素環 |
| US7206308B2 (en) * | 2001-12-22 | 2007-04-17 | International Business Machines Corporation | Method of providing a non-blocking routing network |
| WO2003089434A2 (en) * | 2002-04-19 | 2003-10-30 | Cellular Genomics, Inc. | IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES METHOD OF MAKING AND METHOD OF USE THEREOF |
| AU2003255528B2 (en) * | 2002-07-10 | 2009-07-16 | Merck Serono Sa | Azolidinone-vinyl fused-benzene derivatives |
| US20050222225A1 (en) * | 2002-07-10 | 2005-10-06 | Applied Research Systems Ars Holding Nv | Use of compounds for increasing spermatozoa motility |
| US7205308B2 (en) | 2002-09-04 | 2007-04-17 | Schering Corporation | Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors |
| ATE362474T1 (de) * | 2002-09-04 | 2007-06-15 | Schering Corp | Pyrazolo(1,5-a)pyrimidine als hemmstoffe cyclin- abhängiger kinasen |
| US20040214872A1 (en) | 2002-09-26 | 2004-10-28 | Pintex Pharmaceuticals, Inc. | Pin1-modulating compounds and methods of use thereof |
| US7557110B2 (en) * | 2003-02-28 | 2009-07-07 | Teijin Pharma Limited | Pyrazolo[1,5-A] pyrimidine derivatives |
| PE20051128A1 (es) * | 2004-02-25 | 2006-01-16 | Schering Corp | Pirazolotriazinas como inhibidores de quinasa |
| PL1786812T3 (pl) * | 2004-09-03 | 2012-04-30 | Merck Serono Sa | Pirydynometylenoazolidynony i ich zastosowanie jako inhibitorów fosfoinozytydów |
| WO2008014219A2 (en) * | 2006-07-24 | 2008-01-31 | Smithkline Beecham Corporation | Thiozolidinedione derivatives as p13 kinase inhibitors |
| FR2907120B1 (fr) * | 2006-10-12 | 2013-01-11 | Sanofi Aventis | Nouveaux derives imidazolones,leur preparation a titre de medicaments,compositions pharmaceutiques,utilisation comme inhibiteurs de proteines kinases notamment cdc7 |
| JP5394404B2 (ja) * | 2008-02-06 | 2014-01-22 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼ阻害剤として有用な置換イミダゾピリダジン類 |
| CN102458412A (zh) * | 2009-05-20 | 2012-05-16 | 赛林药物股份有限公司 | 作为激酶抑制剂的吡唑并嘧啶和相关杂环 |
-
2010
- 2010-11-15 PL PL10834934T patent/PL2509602T3/pl unknown
- 2010-11-15 RU RU2012127792A patent/RU2607453C2/ru active
- 2010-11-15 AU AU2010326268A patent/AU2010326268B2/en active Active
- 2010-11-15 CN CN2010800630542A patent/CN102762208A/zh active Pending
- 2010-11-15 WO PCT/US2010/056712 patent/WO2011068667A1/en not_active Ceased
- 2010-11-15 ES ES10834934.1T patent/ES2629170T3/es active Active
- 2010-11-15 SG SG2012041034A patent/SG181507A1/en unknown
- 2010-11-15 EP EP10834934.1A patent/EP2509602B9/en active Active
- 2010-11-15 BR BR112012013508A patent/BR112012013508A2/pt not_active IP Right Cessation
- 2010-11-15 US US12/946,759 patent/US8575177B2/en active Active
- 2010-11-15 KR KR1020127017450A patent/KR101851130B1/ko active Active
- 2010-11-15 CA CA2782684A patent/CA2782684C/en active Active
- 2010-11-15 JP JP2012542060A patent/JP5802676B2/ja active Active
-
2012
- 2012-05-31 IL IL220086A patent/IL220086B/en active IP Right Grant
-
2013
- 2013-09-13 US US14/026,591 patent/US9303033B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013512903A5 (enExample) | ||
| RU2012127792A (ru) | Пиразолопиримидины и родственные гетероциклы как ск2 ингибиторы | |
| ES2660831T3 (es) | Derivados de imidazol condensados útiles como inhibidores de IDO | |
| JP2016517857A5 (enExample) | ||
| JP2017511360A5 (enExample) | ||
| JP2016513737A5 (enExample) | ||
| RU2015118647A (ru) | Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr | |
| JP2014500295A5 (enExample) | ||
| JP2015506348A5 (enExample) | ||
| JP2016516043A5 (enExample) | ||
| JP2010523522A5 (enExample) | ||
| JP2017528498A5 (enExample) | ||
| JP2016509047A5 (enExample) | ||
| HUE031367T2 (en) | A pharmaceutical combination comprising an Hsp 90 inhibitor and a mTOR inhibitor | |
| JP2016513661A5 (enExample) | ||
| JP2007529421A5 (enExample) | ||
| JP2013532652A5 (enExample) | ||
| RU2018127728A (ru) | Слитые трициклические гетероциклические соединения в качестве ингибиторов интегразы вич | |
| JP2017508782A5 (enExample) | ||
| RU2016131189A (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНДУКТОРОВ ЧЕЛОВЕЧЕСКОГО ИНТЕРФЕРОНА | |
| WO2018152548A4 (en) | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) | |
| JP2016513696A5 (enExample) | ||
| JP2016525104A5 (enExample) | ||
| JP2018502101A5 (enExample) | ||
| RU2015121037A (ru) | Производные фенилэтилпиридина в качестве ингибиторов pde-4 |